Exclusive Summary

• The innovator's patent expired decades ago, presenting zero IP barriers and allowing overseas distributors to initiate immediate registration and commercial sales without litigation risks.
• Targeting approximately 260 million asthma patients and globally widespread allergic rhinitis demographics, this classic oral staple maintains massive and stable demand in the primary care markets of LMICs.
• Backed by China's highly integrated API and finished formulation supply chain, the ultra-low manufacturing cost ensures strong pricing competitiveness and profound profit margins for local public tenders and retail channels.
• Supported by international GMP-compliant manufacturing systems and comprehensive CTD dossiers, it significantly expedites the regulatory submission and approval timelines with local Ministries of Health.